Products
Olaratumab was approved in the United States and EU in 2016 and in many countries in 2017 as a concentrate for the preparation of an infusion solution (Lartruvo).
Structure and properties
Olaratumab is a human IgG1 monoclonal antibody that binds to PDGFRα. It is produced by biotechnological methods and has a molecular weight of 154 kDa.
Effects
Olaratumab (ATC L01XC27) has antitumor properties. The effects are due to binding to PDGFRα (platelet derived growth factor receptor α). This is a receptor tyrosine kinase expressed on tumor and stromal cells. The interaction prevents binding with PDGF AA, BB and CC ligands and receptor activation and inhibits tumor growth. Olaratumab has a median half-life of 11 days.
Indications
In combination with doxorubicin for the treatment of advanced soft tissue sarcoma.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Contraindications
Olaratumab is contraindicated in the presence of hypersensitivity. For complete precautions, see the drug label.
Interactions
Olaratumab should not be combined with live vaccines.
Adverse effects
The most common potential adverse effects include nausea, musculoskeletal pain, neutropenia, and mucosal inflammation.
